We have advised Zentiva Group a.s. (Zentiva), a portfolio company of Advent and a leader in the development, production, and distribution of high-quality generic medicines and therapeutic solutions, in its acquisition of five heritage brands from Aboca S.p.A. (Aboca), a historic Italian company specialising in 100% natural pharmaceutical products.
This acquisition forms part of Zentiva’s growth strategy, aimed at reinforcing its leadership in the European consumer healthcare market by expanding its portfolio in the health and wellness segment—with a particular focus on natural solutions that meet growing consumer demand for effective, sustainable, plant-based products.
As of 30ᵗʰ June 2025, five new brands, Propol2 EMF, Ruscoven, Serenil, Fisiodepur, and Finocarbo, will be integrated into Zentiva’s potfolio. These additions will strengthen the company’s position in key therapeutic areas such as respiratory health, circulatory system support, and sleep disorders. In addition to its existing presence in Italy, Spain, and France, the agreement will also facilitate further expansion into Portugal, Poland, Romania, and Greece.
Zentiva is a pan-European company headquartered in Prague, with seven production sites and 31 subsidiaries across 35 countries, both in and outside of Europe. The company serves over 100 million people worldwide and operates its own research and manufacturing facilities. In 2024 alone, Zentiva completed more than 75 business development agreements to enhance and diversify its product offering.
We supported Zentiva throughout the entire acquisition process, from the identification of the opportunity to the completion of the deal.
